Treatment of tuberculosis in HIV-infected patients:: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin

被引：25
|
作者：
Moreno, S [1 ]
Podzamczer, D
Blázquez, R
Iribarren, JA
Ferrer, E
Reparaz, J
Peña, JM
Cabrero, E
Usán, L
机构：
[1] Hosp Ramon & Cajal, Dept Infect Dis, E-28034 Madrid, Spain
[2] Bellvitge Hosp, Dept Infect Dis, Barcelona, Spain
[3] Hosp Morales Meseguer, Dept Microbiol & Infect Dis, Murcia, Spain
[4] Hosp NS Aranzazu, Dept Infect Dis, San Sebastian, Spain
[5] Hosp Navarra, Dept Infect Dis, Pamplona, Spain
[6] Hosp La Paz, AIDS Unit, Madrid, Spain
[7] Abbott Labs, Dept Med, Madrid, Spain
来源：
AIDS | 2001年 / 15卷 / 09期
关键词：
D O I：
10.1097/00002030-200106150-00018
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：1185 / 1187
页数：3
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF ONCE DAILY MARAVIROC PLUS LOPINAVIR/RITONAVIR IN ANTIRETROVIRAL NAIVE HIV-INFECTED PATIENTS
    Nozza, S.
    Antinori, A.
    Mazzotta, F.
    Calbi, C.
    Di Pietro, M.
    Galli, L.
    Tommasi, C.
    Fezza, R.
    Narciso, P.
    Tambussi, G.
    Lazzarin, A.
    INFECTION, 2011, 39 : S34 - S35
  • [2] Antiretroviral Treatment Efficacy and Safety in Older HIV-Infected Adults
    Jourjy, Jacqueline
    Dahl, Keelin
    Huesgen, Emily
    PHARMACOTHERAPY, 2015, 35 (12): : 1140 - 1151
  • [3] Efficacy and Safety of Ritonavir Dose Reduction Based on the Tipranavir Inhibitory Quotient in HIV-Infected Patients on Salvage Antiretroviral Therapy with Tipranavir/Ritonavir
    Molto, Jose
    Valle, Marta
    Ramon Santos, Jose
    Miranda, Cristina
    Cedeno, Samandhy
    Negredo, Eugenia
    Yritia, Mercedes
    Videla, Sebastian
    Clotet, Bonaventura
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (11) : 1191 - 1196
  • [4] Efficacy of amprenavir, ritonavir and efavirenz in treatment experienced HIV-infected patients
    Römer, K
    Salzberger, B
    Franzen, C
    Waldschmidt, D
    Fätkenheuer, G
    AIDS, 2000, 14 : S31 - S31
  • [5] Evaluation of the Efficacy and Safety of Changes in Antiretroviral Regimens for HIV-infected Patients
    Tanaka, Hiroyuki
    Wada, Tatsuhiko
    Takayama, Yoko
    Matsumoto, Keisuke
    Atsuda, Koichiro
    Satoh, Mitsutoshi
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2014, 17 (03): : 316 - 323
  • [6] Paradoxical aggravation of tuberculosis after antiretroviral treatment in HIV-infected patients
    Duval, X
    Trad, S
    Le Moing, V
    Longuet, P
    Leport, C
    Vildé, JL
    PRESSE MEDICALE, 2001, 30 (05): : 213 - 216
  • [7] Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis
    Gurumurthy, P
    Ramachandran, G
    Kumar, AKH
    Rajasekaran, S
    Padmapriyadarsini, C
    Swaminathan, S
    Venkatesan, P
    Sekar, L
    Kumar, S
    Krishnarajasekhar, OR
    Paramesh, P
    CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) : 280 - 283
  • [8] Risk factors for tuberculosis among HIV-infected patients receiving antiretroviral treatment
    Lawn, SD
    Badri, M
    Wood, R
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (10) : 1348 - 1348
  • [9] Safety and efficacy of lopinavir/ritonavir (LPV/r) and tenofovir (TDF) in treatment-experienced HIV-infected patients
    Cimoch, PJ
    Ruane, P
    Mathews, C
    Tat, SM
    Luber, AD
    Ballard, C
    Okamoto, C
    Kakuda, TN
    XIV INTERNATIONAL AIDS CONFERENCE: CLINICAL SCIENCES AND CARE, 2002, : 157 - 161
  • [10] Clinical update: Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin (Reprinted)
    不详
    ANNALS OF PHARMACOTHERAPY, 1997, 31 (03) : 387 - 387
12345